RxDoctor Payments Data

Sunita Chhabra, MD

Internal Medicine · Woodbridge, CTNPI 1568496552

Payments from drug & device makers

$3,927in general payments, 2019–2025

Across 172 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$857
  • Novo Nordisk$522
  • Astellas Pharma US Inc$296
  • GSK$278
  • Lilly USA, LLC$238
  • Pfizer$224
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$3,927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,927 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$38,279
Medicare patients
121
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$29,429
EliquisApixaban58$29,314
OzempicSemaglutide27$25,424
JanuviaSitagliptin Phosphate22$11,894
XareltoRivaroxaban22$10,587
LinzessLinaclotide12$7,180
Breo ElliptaFluticasone/Vilanterol13$5,100
BrilintaTicagrelor19$4,791
Atorvastatin Calcium179$2,596
Pantoprazole Sodium98$2,240
Levothyroxine Sodium164$1,943
Rosuvastatin Calcium147$1,908
Lubiprostone12$1,525
Amlodipine Besylate160$1,513
Lidocaine19$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$127$29,42942 claims
PfizerEliquis$224$29,31458 claims
Novo NordiskOzempic$522$25,42427 claims
MerckJanuvia$38$11,89422 claims
Johnson & JohnsonXarelto$49$10,58722 claims
AbbVieLinzess$37$7,18012 claims
GSKBreo Ellipta$278$5,10013 claims
AstraZenecaBrilinta$857$4,79119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Woodbridge

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →